Literature DB >> 28736944

Short-term acipimox treatment is associated with decreased cardiac parasympathetic modulation.

Esben Thyssen Vestergaard1,2, Simon Lebech Cichosz3, Niels Møller1,4, Jens Otto Lunde Jørgensen1,4, Jesper Fleischer1.   

Abstract

AIMS: The nicotinic acid analogue acipimox is an antilipolytic agent, which acutely inhibits lipolysis and suppresses systemic levels of free fatty acids (FFA) and improves insulin sensitivity in obese patients. These effects of acipimox are transient due to a counter-regulatory increase in growth hormone levels that reverse the antilipolytic effect of acipimox. Hypopituitary patients constitute a viable model to study the growth hormone-independent effects of acipimox and the impact of isolated changes in FFA concentrations and insulin sensitivity on parasympathetic nervous activity. The aim of the present study was to investigate if pharmacological antilipolysis with acipimox acutely affects autonomic tone.
METHODS: We studied heart rate variability as a measure of autonomic tone in eight hypopituitary men with and without acipimox treatment. The standard deviation of normal-to-normal intervals, root mean square of successive differences and high frequency were measured as heart rate variability parameters. The patients were studied in the basal and insulin-stimulated state with clamped plasma glucose on two occasions in a randomized, double-blind and placebo-controlled crossover study.
RESULTS: Plasma glucose (4.7 vs. 4.9 mmol l-1 , P = 0.02) and serum FFA (0.05 vs. 0.41 mmol l-1 , P < 0.001) were significantly decreased during acipimox treatment. Acipimox had an inhibitory effect on standard deviation of normal-to-normal intervals (41.3 vs. 45.3 ms, P = 0.01), root mean square of successive differences (23.2 vs. 11 ms, P = 0.03) and high frequency (3.79 vs 3.60 ln (ms2 ), P = 0.02) and these effects were reversed during clamping.
CONCLUSIONS: Short-term inhibition of lipolysis by acipimox treatment lowered circulating FFA levels, improved insulin sensitivity, and was accompanied by reduced parasympathetic tone. The effect of acipimox on the parasympathetic modulation was reversed by hyperinsulinaemia.
© 2017 The British Pharmacological Society.

Entities:  

Keywords:  acipimox; heart rate variability; lipolysis

Mesh:

Substances:

Year:  2017        PMID: 28736944      PMCID: PMC5698577          DOI: 10.1111/bcp.13384

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  31 in total

1.  The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus.

Authors:  P J RANDLE; P B GARLAND; C N HALES; E A NEWSHOLME
Journal:  Lancet       Date:  1963-04-13       Impact factor: 79.321

2.  Short-term acipimox treatment is associated with decreased cardiac parasympathetic modulation.

Authors:  Esben Thyssen Vestergaard; Simon Lebech Cichosz; Niels Møller; Jens Otto Lunde Jørgensen; Jesper Fleischer
Journal:  Br J Clin Pharmacol       Date:  2017-08-24       Impact factor: 4.335

3.  Selective parasympathetic innervation of subcutaneous and intra-abdominal fat--functional implications.

Authors:  Felix Kreier; Eric Fliers; Peter J Voshol; Corbert G Van Eden; Louis M Havekes; Andries Kalsbeek; Caroline L Van Heijningen; Arja A Sluiter; Thomas C Mettenleiter; Johannes A Romijn; Hans P Sauerwein; Ruud M Buijs
Journal:  J Clin Invest       Date:  2002-11       Impact factor: 14.808

4.  Acipimox-mediated plasma free fatty acid depression per se stimulates growth hormone (GH) secretion in normal subjects and potentiates the response to other GH-releasing stimuli.

Authors:  R Peino; F Cordido; A Peñalva; C V Alvarez; C Dieguez; F F Casanueva
Journal:  J Clin Endocrinol Metab       Date:  1996-03       Impact factor: 5.958

5.  Power spectrum analysis of heart rate fluctuation: a quantitative probe of beat-to-beat cardiovascular control.

Authors:  S Akselrod; D Gordon; F A Ubel; D C Shannon; A C Berger; R J Cohen
Journal:  Science       Date:  1981-07-10       Impact factor: 47.728

6.  Comparing spectra of a series of point events particularly for heart rate variability data.

Authors:  R W DeBoer; J M Karemaker; J Strackee
Journal:  IEEE Trans Biomed Eng       Date:  1984-04       Impact factor: 4.538

Review 7.  Interaction between leptin and sympathetic nervous system in hypertension.

Authors:  W G Haynes
Journal:  Curr Hypertens Rep       Date:  2000-06       Impact factor: 5.369

8.  Fatty acid oxidation and triacylglycerol hydrolysis are enhanced after chronic leptin treatment in rats.

Authors:  Gregory R Steinberg; Arend Bonen; David J Dyck
Journal:  Am J Physiol Endocrinol Metab       Date:  2002-03       Impact factor: 4.310

Review 9.  Cardiac autonomic neuropathy in diabetes: a clinical perspective.

Authors:  Rodica Pop-Busui
Journal:  Diabetes Care       Date:  2010-02       Impact factor: 19.112

10.  Evidence for a direct effect of the NAD+ precursor acipimox on muscle mitochondrial function in humans.

Authors:  Tineke van de Weijer; Esther Phielix; Lena Bilet; Evan G Williams; Eduardo R Ropelle; Alessandra Bierwagen; Roshan Livingstone; Peter Nowotny; Lauren M Sparks; Sabina Paglialunga; Julia Szendroedi; Bas Havekes; Norman Moullan; Eija Pirinen; Jong-Hee Hwang; Vera B Schrauwen-Hinderling; Matthijs K C Hesselink; Johan Auwerx; Michael Roden; Patrick Schrauwen
Journal:  Diabetes       Date:  2014-10-28       Impact factor: 9.461

View more
  2 in total

1.  Short-term acipimox treatment is associated with decreased cardiac parasympathetic modulation.

Authors:  Esben Thyssen Vestergaard; Simon Lebech Cichosz; Niels Møller; Jens Otto Lunde Jørgensen; Jesper Fleischer
Journal:  Br J Clin Pharmacol       Date:  2017-08-24       Impact factor: 4.335

Review 2.  The effects of nicotinamide adenine dinucleotide in cardiovascular diseases: Molecular mechanisms, roles and therapeutic potential.

Authors:  Xiaokai Zhang; Yang Zhang; Aijun Sun; Junbo Ge
Journal:  Genes Dis       Date:  2021-04-24
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.